Cancer and the microbiota
Open accessThe DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
A host’s microbiota may increase, diminish, or have no effect at all on cancer susceptibility. Assigning causal roles in cancer to specific microbes and microbiotas, unraveling host-microbiota interactions with environmental factors in carcinogenesis, and exploiting such knowledge for cancer diagnosis and treatment are areas of intensive interest. This Review considers how microbes and the microbiota may amplify or mitigate carcinogenesis, responsiveness to cancer therapeutics, and cancer-associated complications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Loss of microbial diversity (dysbiosis) is associated with chronic health conditions (26–28) and cancer (8–10), and is also associated with poor outcomes to certain forms of cancer therapy including allogeneic stem cell transplant (29).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [8]
In the citing paper
“It has recently emerged that factors beyond tumor genomics influence cancer development and therapeutic responses (4–7), including host factors such as the gastrointestinal (gut) microbiome (8–10).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [8]
In the citing paper
“their gene count that exceeds the human genome’s gene count by ~100-fold and enables diverse metabolic programming”
From The microbiome and human cancer (2021) · cites this paper as [31]
In the citing paper
“the number of microbes that inhabit the human body (roughly equal to the number of human cells)”
From The microbiome and human cancer (2021) · cites this paper as [31]
In the citing paper
“their effects on host immune system development and activity, including antitumor immunosurveillance (27–31).”
From The microbiome and human cancer (2021) · cites this paper as [31]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
A core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
Self-citationMetabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Inflammatory Mechanisms in Obesity
Gregor, M. F., & Hotamisligil, G. S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101322 · Cited by 3,754
Research works printed but not linked: 1
- 10.1111/j.1572-0241.2000.01860.x · doi:10.1111/j.1572-0241.2000.01860.x · Paper page
Cited by
Items 301–400 of 1,001
Crosstalk between autophagy and microbiota in cancer progression
Wang, Y., Du, J., Wu, X., Abdelrehem, A., Ren, Y., Liu, C., Zhou, X., & Wang, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01461-0 · Cited by 64
“also indicated that the ways in which microbes and microbiota contribute to carcinogenesis, whether by enhancing or diminishing a host’s risk, fall into three broad categories: (i) altering the balance of host cell proliferation and death, (ii) guiding immune system function, and (iii) influencing the metabolism of ho…”
BackgroundRole of the Microbiota in Lung Cancer: Insights on Prevention and Treatment
Pizzo, F., Maroccia, Z., Ferri, I. H., & Fiorentini, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116138 · Cited by 61
“In fact, it is widely known that bacteria can modulate immune responses, inflammatory status, metabolism, and cell proliferation, and to mediate epigenetic and genotypic processes [44].”
BackgroundHepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy
Luo, W., Guo, S., Zhou, Y., Zhao, J., Wang, M., Sang, L.-X., Chang, B., & Wang, B. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.873160 · Cited by 65
“Cancer occurs when DNA damage exceeds the repair capacity of the host cell (Garrett, 2015).”
BackgroundZhang, W., Li, J., Lu, S., Han, N., Miao, J., Zhang, T., Qiang, Y., Kong, Y., Wang, H., Gao, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36318-y · Cited by 63
An Update on the Effects of Probiotics on Gastrointestinal Cancers
Davoodvandi, A., Fallahi, F., Tamtaji, O. R., Tajiknia, V., Banikazemi, Z., Fathizadeh, H., Abbasi‐Kolli, M., Aschner, M., Ghandali, M., Sahebkar, A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.680400 · Cited by 61
“…have also been proven to act as signaling molecules affecting the immune system, cell death, and proliferation as well as intestinal hormone production and lipogenesis, which explains their crucial role in epithelial integrity maintenance (Garrett, 2015; Requena et al., 2018; Górska et al., 2019).”
BackgroundStreptococcus mutans promotes tumor progression in oral squamous cell carcinoma
Tsai, M., Chen, Y., Chen, W., & Chen, M. (2022) · Journal of Cancer · doi:10.7150/jca.73310 · Cited by 62
“The IL-6/STAT3 pathway activation has been implicated in microbiome-induced tumor progression [5].”
BackgroundInfluentialPathogenetic Impact of Bacterial–Fungal Interactions
Nogueira, F., Sharghi, S., Kuchler, K., & Lion, T. (2019) · Microorganisms · doi:10.3390/microorganisms7100459 · Cited by 68
The microbiome(s) and cancer: know thy neighbor(s)
González‐Sánchez, P., & DeNicola, G. M. (2021) · The Journal of Pathology · doi:10.1002/path.5661 · Cited by 61
“One mechanism is the use of barriers to physically separate microbial and host cells, preventing uncontrolled systemic spread of potentially dangerous pathogens [80].”
BackgroundThe Microbiome and Gynecologic Cancer: Current Evidence and Future Opportunities
Chambers, L., Bussies, P. L., Vargas, R., Esakov, E. L., Tewari, S., Reizes, O., & Michener, C. M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01079-x · Cited by 62
Zhang, J., Wan, S., Zhou, H., Du, J., Li, Y., Zhu, H., Weng, L., Ding, X., & Wang, L. (2024) · ACS Nano · doi:10.1021/acsnano.3c13194 · Cited by 61
Microbiome bacterial influencers of host immunity and response to immunotherapy
Yousefi, Y., Baines, K. J., & Vareki, S. M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101487 · Cited by 71
Cascardi, E., Cazzato, G., Daniele, A., Silvestris, E., Cormio, G., Vagno, G. D., Malvası, A., Loizzi, V., Scacco, S., Pinto, V., et al. (2022) · Biology · doi:10.3390/biology11081114 · Cited by 64
“On the other hand, some dysbiotic bacterial communities seem to cause immune dysregulation, favoring a tumor-promoting microenvironment [128], and may play an important role in CC progression [129].”
BackgroundKumar, R., Herold, J. L., Taylor, J. C., Xu, J., & Xu, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-19941-7 · Cited by 60
Sansone, C., Bruno, A., Piscitelli, C., Baci, D., Fontana, A., Brunet, C., Noonan, D. M., & Albini, A. (2021) · Cells · doi:10.3390/cells10020231 · Cited by 58
Advances in Nanodelivery of Green Tea Catechins to Enhance the Anticancer Activity
Jiang, Y., Jiang, Z., Ma, L., & Huang, Q. (2021) · Molecules · doi:10.3390/molecules26113301 · Cited by 56
“The relationship between gut microbiota and cancer development has been actively investigated in recent decades [69,70].”
BackgroundBiofilm and Cancer: Interactions and Future Directions for Cancer Therapy
Choi, E., Murray, B., & Choi, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612836 · Cited by 62
“Fusobacterium nucleatum activates NF-κB, a critical factor for cancer, promoting inflammation [13,18].”
BackgroundPeriodontal Pathogens Promote Oral Squamous Cell Carcinoma by Regulating ATR and NLRP3 Inflammasome
Yao, Y., Shen, X., Zhou, M., & Tang, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722797 · Cited by 60
“As we all know, inflammation and persistent infection might contribute to various human malignancies and the inflammasome-mediated immune mechanisms, and the monitoring mechanisms based on DNA damage responses (DDRs) played an important role in the progression of inflammatory tumors (10), failure of which led to accum…”
BackgroundImpact of diet on human gut microbiome and disease risk
Mansour, S. R., Moustafa, M., Saad, B. M., hamed, R. A., & Moustafa, A. (2021) · New Microbes and New Infections · doi:10.1016/j.nmni.2021.100845 · Cited by 62
“gastric, colorectal, liver and pancreatic cancers [48,49].”
Modulating Microbiota as a New Strategy for Breast Cancer Prevention and Treatment
Wu, H., Ganguly, S., & Tollefsbol, T. O. (2022) · Microorganisms · doi:10.3390/microorganisms10091727 · Cited by 56
The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental?
Hekmatshoar, Y., Saadat, Y. R., Khatibi, S. M. H., Özkan, T., Vahed, F. Z., Nariman‐Saleh‐Fam, Z., Gargari, B. P., Sunguroğlu, A., & Vahed, S. Z. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116680 · Cited by 56
Fernández-Edreira, D., Liñares-Blanco, J., & Fernandez-Lozano, C. (2021) · Expert Systems with Applications · doi:10.1016/j.eswa.2021.115648 · Cited by 55
López‐Gómez, L., Alcorta, A., & Abalo, R. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13101487 · Cited by 51
Bai, J., Behera, M., & Bruner, D. W. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3982-3 · Cited by 60
Alterations of Gut Microbiota in Cholestatic Infants and Their Correlation With Hepatic Function
Guo, C., Li, Y., Wang, P., Li, Y., Qiu, C., Li, M., Wang, D., Zhao, R., Li, D., Wang, Y., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02682 · Cited by 71
Jiang, Z., Wang, J., Shen, Z., Zhang, Z., & Wang, S. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.774330 · Cited by 60
Profiling the Bladder Microbiota in Patients With Bladder Cancer
Parra-Grande, M., Oré-Arce, M., Martinez-Priego, L., D’Auria, G., Rossello-Mora, R. A., Lillo, M., Sempere, A., Lumbreras, B., & Sánchez, V. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.718776 · Cited by 55
“process of carcinogenesis (Kostic et al., 2012; Lu et al., 2014; Garrett, 2015; Neto et al., 2015; Alfano et al., 2016).”
BackgroundTumor microbiome metabolism: A game changer in cancer development and therapy
Zhou, X., Kandalai, S., Hossain, F., & Zheng, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.933407 · Cited by 57
Streptococcus Pneumoniae Promotes Lung Cancer Development and Progression
Li, N., Zhou, H., Holden, V. K., Deepak, J., Dhilipkannah, P., Todd, N. W., Stass, S. A., & Jiang, F. (2022) · iScience · doi:10.1016/j.isci.2022.105923 · Cited by 62
Filippou, C., Themistocleous, S., Marangos, G., Panayiotou, Y., Fyrilla, M., Kousparou, C. A., Pana, Z. D., Tsioutis, C., Johnson, E. O., & Yiallouris, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021110 · Cited by 51
“BC pathogenesis is frequently linked to sustained inflammation, incited by intestinal bacteria that activate NF-κ B, subsequently releasing pro-inflammatory cytokines such as TNF-alpha [82–84].”
BackgroundTumor microbiome: roles in tumor initiation, progression, and therapy
Zhang, S., Huang, J., Jiang, Z., Tong, H., Ma, X., & Liu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00248-9 · Cited by 63
The tumor microbiome in cancer progression: mechanisms and therapeutic potential
Zhang, W., Xiang, Y., Ren, H., Liu, Y., Wang, Q., Ran, M., Zhou, W., Lu, T., Zheng, X., Qiao, C., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02403-w · Cited by 64
“Changes in the β-catenin signaling pathway are frequently observed in various malignancies, including CRC, GC, and primary liver cancer, and may be influenced by certain TM [165, 166].”
Xia, Y., Zhu, J., Xu, Y., Zhang, H., Zou, F., & Meng, X. (2020) · Chemosphere · doi:10.1016/j.chemosphere.2020.127220 · Cited by 51
Sánchez-Alcoholado, L., Laborda-Illanes, A., Otero, A., Ordóñez, R., González-González, A., Plaza-Andrades, I., Ramos-Molina, B., Gómez-Millán, J., & Queipo-Ortuño, M. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179549 · Cited by 49
“The loss of microbial diversity has been associated with chronic health conditions [25–27] and cancer [27,28] as well as with poor outcomes to certain forms of cancer therapy [29–31].”
BackgroundDesai, S., Dharavath, B., Manavalan, S., Rane, A., Redhu, A. K., Sunder, R., Butle, A. B., Mishra, R., Joshi, A., Togar, T., et al. (2022) · NAR Cancer · doi:10.1093/narcan/zcac006 · Cited by 54
Wu, N., Feng, Y., Lyu, N., Wang, D., Yu, W., & Hu, Y. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i18.1981 · Cited by 53
Natural quinazolinones: From a treasure house to promising anticancer leads
Li, H., Fu, G., & Zhong, W. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114915 · Cited by 49
Microbial infection, inflammation and epithelial ovarian cancer
Xie, X., Yang, M., Ding, Y., & Chen, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.6388 · Cited by 55
Rathje, K., Mortzfeld, B. M., Hoeppner, M. P., Taubenheim, J., Bosch, T. C. G., & Klimovich, A. V. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008375 · Cited by 54
“A causal connection between microbiota and cancerogenesis is being increasingly appreciated [58,59].”
BackgroundLi, W. T., Iyangar, A. S., Reddy, R. G., Chakladar, J., Bhargava, V., Sakamoto, K., Ongkeko, W. M., & Rajasekaran, M. R. (2021) · Cancers · doi:10.3390/cancers13153649 · Cited by 49
“In human colon cancer, butyrate-producing bacteria could be either tumor-promoting or anti-tumor, depending on the phenotype of the cancer [24].”
BackgroundHarness the functions of gut microbiome in tumorigenesis for cancer treatment
Lee, M. (2021) · Cancer Communications · doi:10.1002/cac2.12200 · Cited by 50
Role of the microbiome in oral cancer occurrence, progression and therapy
Li, Z., Liu, Y., & Zhang, L. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105638 · Cited by 55
Li, Y., Huang, Y., Liang, H., Wang, W., Li, B., Liu, T., Huang, Y., Zhang, Z., Qin, Y., Zhou, X., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1243390 · Cited by 67
“Noteworthy, tumor genetics and butyrate concentrations were considered the key factors that led to the opposite effects of SCFAs on carcinogenesis between these investigations mentioned above (49, 50).”
BackgroundFu, Y., Li, J., Cai, W., Huang, Y., Liu, X., Ma, Z., Tang, Z., Bian, X., Zheng, J., Jiang, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.018 · Cited by 48
“And the pro-tumorigenic roles of microbiota in tumorigenesis could attribute to the following mechanisms 1,152,164 : (i) facilitating pro-carcinogenic inflammatory responses.”
BackgroundInfluentialDietary Factors in the Control of Gut Homeostasis, Intestinal Stem Cells, and Colorectal Cancer
Francescangeli, F., Angelis, M. L. D., & Zeuner, A. (2019) · Nutrients · doi:10.3390/nu11122936 · Cited by 56
“Pathological conditions that have been linked (with variable strength) to microbiota alterations range from luminal diseases such as inflammatory bowel diseases (IBD) [85] and irritable bowel syndrome (IBS) [86] to metabolic diseases such obesity and diabetes [87], allergic diseases [88], neurodevelopmental disorders…”
BackgroundOliva, M., Schneeberger, P. H. H., Rey, V., Cho, M., Taylor, R., Hansen, A. R., Taylor, K., Hosni, A., Bayley, A., Hope, A. J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01253-1 · Cited by 51
Microbiome in cancer progression and therapy
Andreeva, N., Gabbasova, R. R., & Grivennikov, S. I. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.09.001 · Cited by 49
Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy
Kouroumalis, E., Tsomidis, I., & Voumvouraki, A. (2023) · Biomedicines · doi:10.3390/biomedicines11041166 · Cited by 58
“In addition, alterations in lipid and glucose metabolism stimulate the production of ROS and cause mutations in the p53 onco-suppressor gene [199,200].”
BackgroundInfluentialWang, W., Cao, J., Fang, Y., Wang, X., Zheng, S., Sharshov, K., & Li, L. (2016) · MicrobiologyOpen · doi:10.1002/mbo3.327 · Cited by 49
Duan, J., Wang, Y., & Jiao, S. (2018) · Cancer Medicine · doi:10.1002/cam4.1722 · Cited by 51
Complex interactions between the microbiome and cancer immune therapy
Schwartz, D. J., Rebeck, O. N., & Dantas, G. A. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1660303 · Cited by 54
Association between the microbiota and women’s cancers – Cause or consequences?
Alizadehmohajer, N., Shojaeifar, S., Nedaeinia, R., Esparvarinha, M., Mohammadi, F., Ferns, G. A., Ghayour‐Mobarhan, M., Manian, M., & Balouchi, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110203 · Cited by 53
Xia, T., Zhang, B., Li, Y., Fang, B., Zhu, X., Xu, B., Zhang, J., Wang, M., & Fang, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112582 · Cited by 47
Marongiu, L., & Allgayer, H. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13100 · Cited by 52
Ni, B., Kong, X., Yan, Y., Fu, B., Zhou, F., & Xu, S. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1091825 · Cited by 49
“Changes in gut flora abundance are closely related to the occurrence and development of cancer (Schwabe and Jobin, 2013; Garrett, 2015).”
BackgroundZhu, C., Liu, C., Wu, Q., Sheng, T., Zhou, R., Ren, E., Zhang, R., Zhao, Z., Shi, J., Shen, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02028-3 · Cited by 55
Microbiota in cancer: current understandings and future perspectives
Yao, Y., Zhu, Y., Chen, K., Chen, J., Li, Y., Li, D., & Wei, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02335-3 · Cited by 61
Colorectal cancer: role of commensal bacteria and bystander effects
Wang, X., & Huycke, M. M. (2015) · Gut Microbes · doi:10.1080/19490976.2015.1103426 · Cited by 46
The Challenge and Potential of Metagenomics in the Clinic
Mulcahy, H., & Workentine, M. L. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00029 · Cited by 55
Alteber, Z., Sharbi‐Yunger, A., Pevsner‐Fischer, M., Blat, D., Roitman, L., Tzehoval, E., Elinav, E., & Eisenbach, L. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12000 · Cited by 45
Progress in characterizing the linkage between Fusobacterium nucleatum and gastrointestinal cancer
Liu, Y., Baba, Y., Ishimoto, T., Iwatsuki, M., Hiyoshi, Y., Miyamoto, Y., Yoshida, N., Wu, R., & Baba, H. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1512-9 · Cited by 50
The Relationship Between Microbial Community and Breast Cancer
Song, X., Wei, C., & Li, X. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.849022 · Cited by 47
“In addition, it may be possible to prevent cancer by using drugs that target bacterial inflammation or genetic toxins (Garrett, 2015).”
BackgroundInfluentialZhao, X., & van der Donk, W. A. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.11.014 · Cited by 46
Host-Microbiome Interaction and Cancer: Potential Application in Precision Medicine
Contreras, A. V., Cocom-Chan, B., Hernández‐Montes, G., Portillo-Bobadilla, T., & Reséndis-Antonio, O. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00606 · Cited by 51
Current status and future perspectives of immunotherapy in bladder cancer treatment
Wu, Z., Liu, J., Dai, R., & Wu, S. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1768-y · Cited by 53
“Physiologically and pathologically, it is anticipated that microbiota play a vital role in influencing human immunity (Garrett, 2015; Zitvogel et al., 2016).”
BackgroundDual and mutual interaction between microbiota and viral infections: a possible treat for COVID-19
Baghbani, T., Nikzad, H., Azadbakht, J., Izadpanah, F., & Kashani, H. H. (2020) · Microbial Cell Factories · doi:10.1186/s12934-020-01483-1 · Cited by 48
A potential therapeutic strategy for prostatic disease by targeting the oral microbiome
Fang, C., Wu, L., Zhu, C., Xie, W., Hu, H., & Zeng, X. (2020) · Medicinal Research Reviews · doi:10.1002/med.21778 · Cited by 51
Hang, Z., Lei, T., Zeng, Z., Cai, S., Bi, W., & Du, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112343 · Cited by 47
Ventolini, G., Vieira‐Baptista, P., Seta, F. D., Verstraelen, H., Hoffmann, R., & Lev‐Sagie, A. (2021) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000646 · Cited by 50
Influence of the microbiota on epigenetics in colorectal cancer
Sun, D., Chen, Y., & Fang, J. (2018) · National Science Review · doi:10.1093/nsr/nwy160 · Cited by 46
Parasite-microbe-host interactions and cancer risk
Dheilly, N. M., Ewald, P. W., Brindley, P. J., Fichorova, R. N., & Thomas, F. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007912 · Cited by 47
Microbe–MUC1 Crosstalk in Cancer-Associated Infections
Bose, M., & Mukherjee, P. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.003 · Cited by 48
Ravegnini, G., Fosso, B., Saverio, V. D., Sammarini, G., Zanotti, F., Rossi, G., Ricci, M., D’Amico, F., Valori, G., Ioli, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249735 · Cited by 51
Urobiome: An outlook on the metagenome of urological diseases
Shoemaker, R., & Kim, J. (2021) · Korean journal of urology · doi:10.4111/icu.20210312 · Cited by 54
“It has been suggested that 20% to 30% of cancers, like gastric cancer, liver cancer, urinary bladder cancer, cholangiocellular neoplasia, and cervical cancer are related to recurring microbial infections [41,45].”
BackgroundRationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Tai, D. W.-M., Choo, S. P., & Chew, V. (2019) · Cancers · doi:10.3390/cancers11121926 · Cited by 45
Zhao, Y., Lin, Z., Sun, K., Zhang, Y., Huang, J., Wang, L., & Yao, J. (2022) · Lecture notes in computer science · doi:10.1007/978-3-031-16434-7_7 · Cited by 61
Tsigalou, C., Paraschaki, A., Bragazzi, N. L., Aftzoglou, K., Stavropoulou, E., Tsakris, Z., Vradelis, S., & Bezirtzoglou, E. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1191126 · Cited by 51
“The host though may respond by producing pro-in fl ammatory cytokines, such as IL-17, -23, TNF-a, which have the characteristic to be also pro-tumorigenic (Garrett, 2015; Skowron et al., 2018).”
Backgroundvon Frieling, J., Fink, C., Hamm, J., Klischies, K., Förster, M., Bosch, T. C. G., Roeder, T., Rosenstiel, P. C., & Sommer, F. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02020 · Cited by 49
Gut-microbiota-on-a-chip: an enabling field for physiological research
Trujillo-de Santiago, G., Lobo-Zegers, M. J., Montes-Fonseca, S. L., Zhang, Y. S., & Alvarez, M. M. (2018) · Microphysiological Systems · doi:10.21037/mps.2018.09.01 · Cited by 43
Is it true that gut microbiota is considered as panacea in cancer therapy?
Farrokhi, A. S., Darabi, N., Yousefi, B., Askandar, R. H., Shariati, M., & Eslami, M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28333 · Cited by 44
“…some cancers such as colon cancer or hepatocarcinoma that bacteria could mediate direct function in cancer generation through supplying oncogenic factors, toxins, or by inflamma- tion induction (Abreu & Peek, 2014; Garrett, 2015; Gur et al., 2015; Louis, Hold, & Flint, 2014; Sears & Garrett, 2014).”
BackgroundZhou, F., Lu, Y., Sun, T., Sun, L. V., Wang, B., Lu, J., Li, Z., Zhu, B., Huang, S., & Ding, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1009530 · Cited by 51
“Frontiers in Immunology 03 influence the effectiveness of chemotherapy in cancer patients (37, 38), which means maintaining a good intestinal flora plays an important role in the treatment of diseases (39).”
BackgroundEnhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells
Foerster, F., Boegel, S., Heck, R., Pickert, G., Rüssel, N., Rosigkeit, S., Bros, M., Strobl, S., Kaps, L., Aslam, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1409929 · Cited by 47
γδ T Cells: Crosstalk Between Microbiota, Chronic Inflammation, and Colorectal Cancer
Yang, Y., Xu, C., Wu, D., Wang, Z., Wu, P., Li, L., Huang, J., & Qiu, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01483 · Cited by 48
The Microbiome in Benign Renal Tissue and in Renal Cell Carcinoma
Heidler, S., Lusuardi, L., Stephan Madersbacher, A., & Freibauer, C. (2019) · Urologia Internationalis · doi:10.1159/000504029 · Cited by 42
Interaction of Gut Microbiota with Endocrine Homeostasis and Thyroid Cancer
Liu, Q., Sun, W., & Zhang, H. (2022) · Cancers · doi:10.3390/cancers14112656 · Cited by 48
“Several bacteria and viruses have been implicated in the development of cancers, including Helicobacter pylori, hepatitis B/C virus, and human papillomavirus [25,26].”
BackgroundGut microbiota diversity in middle-aged and elderly patients with end-stage diabetic kidney disease
Chen, R., Zhu, D., Yang, R., Wu, Z., Xu, N., Chen, F., Zhang, S., Chen, H., Li, M., & Hou, K. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-2926 · Cited by 47
“Once this balance is upset, it can lead to various gastrointestinal and even extra-gastrointestinal diseases, including obesity (16), hypertension (17), cancer (18), depression (19), and cardiovascular disease (20).”
Xie, X., Li, Q., Jia, L., Yuan, H., Guo, T., & Meng, T. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202954 · Cited by 42
Risk of cancer in patients with constipation
Sundbøll, J., Thygesen, S. K., Veres, K., Liao, D., Zhao, J., Gregersen, H. N., & Sørensen, H. T. (2019) · Clinical Epidemiology · doi:10.2147/clep.s205957 · Cited by 47
“disseminate to other locations in the body and thereby contribute to cancer development, onset, or progression.(14,15) Third, any association with constipation also may be due to reverse causation, ie, gastrointestinal (GI) cancers may cause constipation before the cancer manifests clinically.”
BackgroundA New Biomarker of Fecal Bacteria for Non-Invasive Diagnosis of Colorectal Cancer
Yao, Y., Ni, H., Wang, X., Xu, Q., Zhang, J., Jiang, L., Wang, B., Song, S., & Zhu, X. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.744049 · Cited by 49
“The occurrence and development of many clinical diseases are closely related to the change of microbiota abundance (Garrett, 2015; Valdes et al., 2018).”
BackgroundZhao, S.-S., Chen, L., Yang, J., Wu, Z.-H., Wang, X., Zhang, Q., Liu, W., & Liu, H. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02612-22 · Cited by 45
“Microbially driven carcinogenesis is also frequently related to global changes in the microbiome (7).”
BackgroundMediterranean diet for cancer prevention and survivorship
Monllor-Tormos, A., García-Vigara, A., Morgan, O., García‐Pérez, M. Á., Mendoza, N., Tarín, J. J., & Cano, A. (2023) · Maturitas · doi:10.1016/j.maturitas.2023.107841 · Cited by 47
Unveiling the intratumoral microbiota within cancer landscapes
Che, S., Yan, Z., Feng, Y., & Hai, Z. (2024) · iScience · doi:10.1016/j.isci.2024.109893 · Cited by 44
“168,226,227 (2) Anti-inflammatory environment promotion : intratumoral-bacteria-derived IL-17 may encourage intratumoral B cell infiltra-tion that supports tumor growth.”
BackgroundConnelly, S., Bristol, J. A., Hubert, S., Subramanian, P., Hasan, N. A., Colwell, R. R., & Kaleko, M. (2017) · Journal of Applied Microbiology · doi:10.1111/jam.13432 · Cited by 47
The promise and challenge of cancer microbiome research
Manzoor, S. S., Doedens, A. M., & Burns, M. B. (2020) · Genome biology · doi:10.1186/s13059-020-02037-9 · Cited by 43
“CPT-11 side effect of severe diarrhea [85, 86].”
Chen, C., Chen, L., Lin, L., Jin, D., Du, Y., & Lyu, J. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11358-z · Cited by 44
“Some microorganisms have host pathway proteins that can participate in carcinogenesis, which can directly regulate cell polarity and growth or participate in cell proliferation, survival, andmigration through certain signal transduction pathways to induce tumorigenesis (Garrett 2015).”
BackgroundThe Mycobiome: Cancer Pathogenesis, Diagnosis, and Therapy
Gamal, A., Elshaer, M. Y. S., Alabdely, M. H., Kadry, A., McCormick, T. S., & Ghannoum, M. A. (2022) · Cancers · doi:10.3390/cancers14122875 · Cited by 45
“Regarding the role of infection with pathogenic organisms, it has been suggested that an imbalance (or dysbiosis) in the abundance of commensal organisms inhabiting various sites of the body (the microbiome) may lead to cancer development and progression [2].”
BackgroundIntratumoral microbiota: implications for cancer onset, progression, and therapy
Wu, J., Zhang, P., Mei, W., & Zeng, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1301506 · Cited by 46
“Intratumoral bacteria may activate PRRs, leading to the secretion of cytokines and chemokines, the facilitation of angiogenesis, and immune cell recruitment (54, 55).”
BackgroundPeriodontal disease and risk of non‐Hodgkin lymphoma in the Health Professionals Follow‐Up Study
Bertrand, K. A., Shingala, J., Evens, A. M., Birmann, B. M., Giovannucci, E. L., & Michaud, D. S. (2016) · International Journal of Cancer · doi:10.1002/ijc.30518 · Cited by 40
Guntaka, N. S., Healy, A. R., Crawford, J. M., Herzon, S. B., & Bruner, S. D. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00479 · Cited by 39
A marginalized two-part Beta regression model for microbiome compositional data
Chai, H., Jiang, H., Lin, L., & Liu, L. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006329 · Cited by 43
The Lung Microbiome: A Central Mediator of Host Inflammation and Metabolism in Lung Cancer Patients?
Weinberg, F. D., Dickson, R. P., Nagrath, D., & Ramnath, N. (2020) · Cancers · doi:10.3390/cancers13010013 · Cited by 42
“It is known that certain intestinal microbiotas promote inflammation and development of gastrointestinal cancers [76,77].”
Background
Metadata
- Authors
- Garrett, W. S.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Garrett, Wendy S.
- ORCID
- Garrett, Wendy S.
- Venue
- Science
- Published
- 2015-04-03
- Volume
- 348
- Issue
- 6230
- Pages
- 80-86
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5535753
- OpenAlex
- W2073924079
- Cited by
- 1,404
- References
- 119
- Citations by year
- 2026: 145 · 2025: 169 · 2024: 169 · 2023: 151 · 2022: 162 · 2021: 141 · 2020: 127 · 2019: 106 · 2018: 77 · 2017: 68 · 2016: 58 · 2015: 29
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (R01CA154426)
- Burroughs Wellcome Career in Medical Sciences Award
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- gut microbiota, cancer susceptibility, carcinogenesis, host-microbe interactions, cancer therapy response, cancer diagnosis
- MeSH terms
- Humans, Immunotherapy, Neoplasms, Carcinogenesis, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.